Accretion Pharmaceuticals Limited - IPO
SMEAccretion Pharmaceuticals Stock Price
Accretion Pharmaceuticals IPO Details
Accretion Pharmaceuticals IPO Subscription
Accretion Pharmaceuticals IPO Application Wise Breakup
Accretion Pharmaceuticals IPO Dates
- 14 May 2025Opening dateOPD
- 16 May 2025Closing dateCOD
- 19 May 2025Basis of AllotmentBOA
- 20 May 2025Initiation of RefundsIOR
- 20 May 2025Credit of SharesCOS
- 21 May 2025Listing dateLID
Accretion Pharmaceuticals IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retain Minimum | 1 | 1200 | ₹121,200 |
| Retain Maximum | 1 | 1200 | ₹121,200 |
| HNI Minimum | 2 | 2400 | ₹242,400 |
Accretion Pharmaceuticals IPO Reservation
Promoter Holding
Accretion Pharmaceuticals IPO Valuations
Accretion Pharmaceuticals Limited Financial Information
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 39.99 | 27.05 | 20.58 | 17.74 |
| Revenue | 35.75 | 33.94 | 29.53 | 22.58 |
| Profit After Tax | 5.24 | 3.88 | 0.10 | 0.08 |
| Net Worth | 13.58 | 5.35 | 3.84 | 3.08 |
| Reserves and Surplus | 5.41 | 1.35 | 0.00 | 0.00 |
| Total Borrowing | 13.79 | 13.48 | 8.47 | 7.61 |
| Amount in ₹ Crore | ||||
About Accretion Pharmaceuticals IPO
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.
The company also offers contract manufacturing services. The Company manufactures and markets Tablets, Capsules, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), and Oral Powder (Sachet, Dry Syrup).
The company also holds ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005 certifications, reflecting its dedication to quality and environmental management systems.
The company's manufacturing unit is located in Ahmedabad, Sanand, Gujarat.
The company has expanded its global footprint, marking its presence in more than 20 countries, including regions in Africa, Southeast Asia, and the Middle East.
Product Portfolio and Services
- Tablets and Capsules – Covering antibiotics, anti-inflammatory, pain management, cardiovascular, and gastrointestinal medicines.
- Oral Liquids and Syrups – Used for respiratory, pediatric, and digestive treatments.
- External Preparations – Including medicated lotions, gels, ointments, and dusting powders for skin care and dermatological treatments.
- Ayurvedic and Herbal Products – Focused on natural wellness solutions for immunity, digestion, and general health.
As of January 2025, the company has 83 employees (including 4 Executive Directors) on its payroll.
Strength Of Accretion Pharmaceuticals IPO
1. Experienced Promoters and Management Team.
2. Consistently supplying quality products to our valued customers in time.
3. Continually improving the quality standards by implementing process control and prevention techniques.
4. Long-standing relationship with clients and suppliers.
5. Quality standards.
6. Legacy Business Process & Management.
7. Strong and experienced R&D team.
Risk Of Accretion Pharmaceuticals IPO
1. We have certain outstanding litigation against us, an adverse outcome of which may adverselyaffect our business, reputation and results of operations.
2. Our Company operates in pharmaceutical sector, which is extensively regulated, any failure onour part to comply with the existing and future statutory and/or regulatory requirements in thepharmaceutical sector could adversely affect our business, results of operations and financialcondition.
3. Our manufacturing units are subject to periodic inspections and audits by regulatory authoritiesand clients. We may be subject to regulatory action which may damage our reputation leadingto an adverse effect on our business, results of operations, financial condition and cash flows.
4. We have a very limited operating history as a Company, which may make it difficult for investorsto evaluate our historical performance or future prospects.
5. We have only one Manufacturing Facility, continued operations of our manufacturing facility iscritical to our business and any disruption in the operation of our manufacturing facility mayhave a material adverse effect on our business, results of operations and financial condition.
6. We generate a significant percentage of our revenue from few clients. The loss of any one or more of our major clients would have a material adverse effect on our business operations and profitability.
7. Our top ten suppliers contribute majority of our purchases. Any loss of business with one or more of them may adversely affect our business operations and profitability.
8. Our business operations are concentrated in the Gujarat, any adverse developments affectingour operations in this region could have a significant impact on our revenue and results ofoperations.
9. We rely on third party providers for carrying out testing of the products manufactured by us.While we do not have direct control over such tests, any occurrence of non-compliance withapplicable regulations, or any errors or omissions during the testing process could adverselyaffect our business, results of operations and financial condition.
10. We do not have long-term agreements with most of our customers and the loss of one or moreof them or a reduction in their demand for our products could adversely affect our business,results of operations, financial condition and cash flows.
Objectives Accretion Pharmaceuticals IPO
1. Capital expenditure towards purchase of new equipment/ machineries, etc.
2. Capital expenditure towards upgradation of existing manufacturing facility.
3. Repayment/prepayment of certain borrowings availed by our Company.
4. Funding working capital requirements.
5. General Corporate Purpose.
Company Contact Details
Accretion Pharmaceuticals Limited
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals, Vasna Chacharvad
Sanand,
Phone: +91-97148 82929
Email: compliance@accretionpharma.com
Website: https://accretionpharma.com/
Registrar Contact Details
Lead Mangers
Jawa Capital Services Private Limited
Market Maker
Gretex Share Broking